Clinical trials - Press Releases

Date	Title	Company
09-Dec-2019	Nouscom – First Patient Dosed in a Phase 1 Trial with NOUS-209, an ‘off-the-shelf’ Neoantigen Cancer Vaccine, in MSI-High Solid Tumors	Nouscom
09-Dec-2019	HVIVO (“HVIVO”) to merge with OPEN ORPHAN PLC (“OPEN ORPHAN”)	The Boards of Open Orphan and hVIVO
09-Dec-2019	Moberg Pharma meets primary endpoint for MOB-015 in a Phase 3 study for the treatment of onychomycosis	Moberg Pharma AB
06-Dec-2019	Key Objectives of The Medical Device and In-Vitro Diagnostic Regulations	PharmaLex
06-Dec-2019	Genmab Achieves USD 100 Million Sales Milestone in DARZALEX® (daratumumab) Collaboration with Janssen	Genmab
06-Dec-2019	First Clinical Study Evaluating Combined tDCS And Behaviour Therapy Could Point To A New Treatment For Depression	Flow Neuroscience
05-Dec-2019	CluePoints’ Risk-Based Quality Management Software Wins Best Technological Development in Clinical Trials at SCRIP Awards 2019	CluePoints
05-Dec-2019	Inceptua appoints new President North America	Inceptua
05-Dec-2019	Lessons from EU Medical Device Regulation compliance preparations	Kallik
04-Dec-2019	New global survey shows misperceptions about lung cancer among the general public	Lung Ambition Alliance
04-Dec-2019	ASLAN PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF AMERICAN DEPOSITARY SHARES	ASLAN Pharmaceuticals
04-Dec-2019	Micro-Leads Announces $10M in Funding for Precision Neuromodulation Therapy	Albany Med
04-Dec-2019	Volker Koscielny, new Chief Medical Officer and new member of the Management Board at Almirall	Almirall
04-Dec-2019	Clinerion and EvidNet partner to drive healthcare forward by extending their global reach and technologies for real-world data-driven solutions.	Clinerion Ltd.
04-Dec-2019	Interview Released Stefan Przyborski, Chairman for SMi’s 3D Cell Culture Conference 2020	SMi Group
04-Dec-2019	Chiesi outlines €350 million investment and announces the development of the first carbon minimal pressurised Metered Dose Inhaler (pMDI) for Asthma and COPD	Chiesi Group
04-Dec-2019	Kancera reports in-depth analysis of the Phase Ib program with KAND567, showing the desired effect on the human immune system	Kancera AB
04-Dec-2019	MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs	MaxCyte, Inc.
04-Dec-2019	Aqilion strengthens its portfolio with two innovative pharmaceutical projects in the fields of inflammation and oncology	AQILION AB
04-Dec-2019	MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ’s Adoptive Cell Therapy Programs	MaxCyte